Tag Archives: alzheimers

Unraveling the Mystery of Alzheimer’s Disease

drew-headshot

Preeminent researchers from around the world gathered recently to tackle the science behind one of medicine’s toughest problems – Alzheimer’s – and elevating the disease as a top global priority. The Global CEO Initiative on Alzheimer’s Disease (CEOi) – a coalition of corporations from the fields of biotechnology, pharmaceuticals, diagnostics, finance, and healthcare – hosted a dinner during the Alzheimer’s Association International Convention (AAIC) in Boston. The CEOi had already taken strides to achieve this Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Alzheimer’s Disease “Robs You of Everything”

Alzheimer’s Disease “Robs You of Everything”

George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood as they raised nine children in New Lenox, a south suburb of Chicago. After the couple’s nest was nearly empty, in what was supposed to be their golden years, George was told he had memory and thinking problems, and later, Alzheimer’s disease. George’s long tenure as a Will County police officer was cut short. He could no longer carry a gun, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Q & A with Eli Lilly’s Eric Siemers

Q+A with Eli Lillys Eric Siemers

In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase 3, double-blind, placebo-controlled studies of the anti-amyloid antibody solanezumab, in patients with mild-to-moderate Alzheimer’s disease. Although cognitive decline was slowed in patients with early stage disease in one trial, and there were also positive signs from the other trial, those findings were not statistically significant. But a secondary analysis conducted independently by a panel of academic researchers pooled data from Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Approving Drugs for Alzheimer’s Disease

Russ Katz

BIOtechNOW delves into the current state of Alzheimer’s disease research with today’s feature on regulatory challenges. Tomorrow, we cover the first Alzheimer’s prevention trial, and on Wednesday, we will explore the societal and economic impact of this devastating disease. The therapies currently approved for Alzheimer’s disease work by treating the patients’ symptoms, improving their cognitive and overall functions. Increasingly, however, experts are intent on slowing or halting the disease process—before it has ravaged patients’ brains. In February, the U.S. Food Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Technology Transfer Symposium: Funding that First $2 Million

2-mill

With creative funding schemes picking up steam and nontraditional funders taking an interest in biotech, what can universities and start-ups expect in their right first-round financing structure? At the BIO Technology Transfer Symposium, a panel examined various funding sources as well as the factors that influence investment decisions and the ins and outs of early stage financing deals. William Tucker, executive director, Innovation Alliances and Services, University of California Office of the President, moderated a Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,